Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Knight Therapeutics Inc.
  6. News
  7. Summary
    GUD   CA4990531069

KNIGHT THERAPEUTICS INC.

(GUD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Knight Therapeutics : in Supply and Distribution Agreement with NASDAQ's Incyte for Tafasitamab and Pemigatinib in Latin America

09/23/2021 | 08:01am EDT


ę MT Newswires 2021
All news about KNIGHT THERAPEUTICS INC.
09/23INCYTE : Signs Supply, Distribution Deal for Tafasitamab, Pemigatinib in Latin America
MT
09/23KNIGHT THERAPEUTICS : in Supply and Distribution Agreement with NASDAQ's Incyte for Tafasi..
MT
09/23KNIGHT THERAPEUTICS BRIEF : Enters into Exclusive Supply and Distribution Agreement with N..
MT
09/23INCYTE : Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with ..
AQ
09/23Knight Therapeutics Inc. Enters into Exclusive Supply and Distribution Agreement with I..
CI
08/16KNIGHT THERAPEUTICS : Reports Second Quarter 2021
AQ
08/16NORTH AMERICAN MORNING BRIEFING : Weak Chinese -3-
DJ
08/13KNIGHT THERAPEUTICS : Posts Q2 EPS of C$0.23; Revenue Reaches Record C$65.8 Million
MT
08/13Tranche Update on Knight Therapeutics Inc.'s Equity Buyback Plan announced on July 10, ..
CI
08/13KNIGHT THERAPEUTICS : Earnings Flash (GUD.TO) KNIGHT THERAPEUTICS Posts Q2 EPS Basic C$0.2..
MT
More news
Financials
Sales 2021 237 M 192 M 192 M
Net income 2021 33,5 M 27,0 M 27,0 M
Net Debt 2021 - - -
P/E ratio 2021 18,0x
Yield 2021 -
Capitalization 644 M 521 M 520 M
Capi. / Sales 2021 2,72x
Capi. / Sales 2022 2,25x
Nbr of Employees 679
Free-Float 81,4%
Chart KNIGHT THERAPEUTICS INC.
Duration : Period :
Knight Therapeutics Inc. Technical Analysis Chart | GUD | CA4990531069 | MarketScreener
Technical analysis trends KNIGHT THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 5,27 CAD
Average target price 7,73 CAD
Spread / Average Target 46,6%
EPS Revisions
Managers and Directors
Samira Sakhia President, Chief Executive Officer & Director
Utchanah Arvind Chief Financial Officer
Jonathan Ross Goodman Executive Chairman
James Charles Gale Lead Independent Director
Robert N. Lande Independent Director
Sector and Competitors